Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CATASTROPHIC CARE DRUG BENEFIT: 14.8% OF ELDERLY PATIENTS

Executive Summary

CATASTROPHIC CARE DRUG BENEFIT: 14.8% OF ELDERLY PATIENTS reached the prescription drug spending threshold of $ 600 that would entitle patients to reimbursement for outpatient drugs in a recent Pharmaceutical Data Services (PDS) survey. Covering a sample of Medicare-eligible patients for the 12 months ended August 1988, PDS found that "more than one of seven of [Medicare eligible patients] have spent more than the required $ 600 deductible on prescription medication in a 12-month period." PDS reported that 14.8% of Medicare patients spent more than $ 600, compared with 4% of total patients receiving prescriptions. Medicare-eligible patients obtained an average of 14.8 prescriptions during the 12 months and spent an average of $ 288.40. The PDS data is based on a new service offered by the McKesson subsidiary called Senior Scripts, which charts prescribing trends among the elderly based on a national sample of more than 3,000 pharmacies. "Among all individuals who have had at least one prescription filed in a 12-month period, the average patient had 6.5 prescriptions filled at an annual cost to the patient of $ 115," PDS noted. "However, among patients with potential coverage under the Catastrophic Health Bill, these averages are more than twice as high." The PDS data indicate that outpatient drug reimbursements under the Catastrophic Care bill, which goes into effect in 1991, may be less than anticipated by Congress, the Health Care Financing Administration, and industry observers. Congress set the $ 600 deductible for 1991 and a $ 652 deductible for 1992, anticipating a level of outpatient drug reimbursements in the range of one in six Medicare patients. After 1992, the outpatient drug benefit deductible will be indexed to ensure that 16.8% of Medicare Part B enrollees during the preceeding year will meet the deductible. A Congressional Budget Office report predicted that the deductible will have to rise to $ 710 by 1993 in order to maintain the 16.8% level of beneficiary eligibility for the drug benefit. Purdue University Pharmacy Economics Professor Stephen Schondelmeyer, PhD, has predicted that the deductible level could rise to $ 1,000 in the early 1990s in order to maintain the 16.8% eligibility level. The American Association of Retired Persons is also predicting that the $ 600 deductible will be too low. The association found that in 1986 about 34% of the elderly population spend more than $ 500 a year on prescription medications.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS015415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel